29 September 2015 - Teva Pharmaceutical Industries Ltd's research chief said on Tuesday the drug industry must act responsibly when it comes to pricing medications, given the mounting anger over the high cost of therapies in the United States.

Democratic presidential candidate Hillary Clinton brought new attention to the issue last week, proposing to cap patients' treatment costs, just one of several ways she would prevent "profiteering" by drugmakers if elected.

"The receptivity of the American public to this indicates that this is an issue, and Teva has to pay attention to it just like other pharma," said Michael Hayden, global head of research and development at Teva, the world's largest generic drugmaker.

"Politically, I can't see this becoming a reality. But the message is more important than the reality, and the message is that we have to be mindful of what the healthcare system can tolerate," Hayden said in an interview at the PSA Pharmaceutical Strategy Conference in New York.

For more details, go to: http://www.reuters.com/article/2015/09/29/us-usa-healthcare-teva-idUSKCN0RT2W220150929